Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted Vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults

Clinical and Vaccine Immunology

Volumn 22, Issue 1, 2015, Pages 46-55

  Aichinger, Gerald ^a   Grohmann Izay, Barbara ^a   Van Der Velden, Maikel V W ^a   Fritsch, Sandor ^a   Koska, Manuela ^a   Portsmouth, Daniel ^a   Hart, Mary Kate ^b   El Amin, Wael ^b   Kistner, Otfried ^a   Barrett, P Noel ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b DynPort Vaccine Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; INFLUENZA A; INFLUENZA A (H9N2); INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H9N2; INJECTION SITE CONTUSION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SHIVERING; SIDE EFFECT; SINGLE RADIAL HEMOLYSIS ASSAY; SWEATING; VERO CELL LINE; VIRUS NEUTRALIZATION; VOLUNTEER; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMAGGLUTINATION INHIBITION TEST; IMMUNODIFFUSION; IMMUNOLOGY; INFLUENZA A VIRUS (H9N2); INFLUENZA, HUMAN; MIDDLE AGED; PATHOLOGY; PROCEDURES; SERODIAGNOSIS; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNODIFFUSION; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84920541055     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00275-14     Document Type: Article

References (55)

1. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. 2008. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371: 1464-1475. http://dx.doi.org/10.1016/S0140-6736(08)60627-3.
2. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF. 1999. Human infection with influenza H9N2. Lancet 354: 916-917. http://dx.doi.org/10.1016/S0140-6736(99)03311-5.
3. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368: 1888-1897. http://dx.doi.org/10.1056/NEJMoa1304459.
4. Chen H, Yuan H, Gao R, Zhang J, Wang D, Xiong Y, Fan G, Yang F, Li X, Zhou J, Zou S, Yang L, Chen T, Dong L, Bo H, Zhao X, Zhang Y, Lan Y, Bai T, Dong J, Li Q, Wang S, Zhang Y, Li H, Gong T, Shi Y, Ni X, Li J, Zhou J, Fan J, Wu J, Zhou X, Hu M, Wan J, Yang W, Li D, Wu G, Feng Z, Gao GF, Wang Y, Jin Q, Liu M, Shu Y. 2014. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 383: 714-721. http://dx.doi.org/10.1016/S0140-6736(14)60111-2.
5. World Health Organization. 2012. Pandemic influenza preparedness and response: a WHO guidance document. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2009/9789241547680-eng.pdf?ua-1.
6. World Health Organization. 2012. Responding to the avian influenza pandemic threat: recommended strategic actions. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/resources/publications/influenza/WHO-CDS-CSR-GIP-05-8-EN.pdf?ua-1.
7. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. 2008. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-2584. http://dx.doi.org/10.1056/NEJMoa073121.
8. Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P. 2009. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces crossreactive memory responses. J Infect Dis 200: 1113-1118. http://dx.doi.org/10.1086/605608.
9. Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ. 2012. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 30: 329-335. http://dx.doi.org/10.1016/j.vaccine.2011.10.088.
10. van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G. 2014. Safety and immunogenicity of a Vero cell culture-derived wholevirus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis 209: 12-23. http://dx.doi.org/10.1093/infdis/jit498.
11. van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. 2012. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 30: 6127-6135. http://dx.doi.org/10.1016/j.vaccine.2012.07.077.
12. Dong G, Luo J, Zhang H, Wang C, Duan M, Deliberto TJ, Nolte DL, Ji G, He H. 2011. Phylogenetic diversity and genotypical complexity of H9N2 influenza A viruses revealed by genomic sequence analysis. PLoS One 6: e17212. http://dx.doi.org/10.1371/journal.pone.0017212.
13. Fusaro A, Monne I, Salviato A, Valastro V, Schivo A, Amarin NM, Gonzalez C, Ismail MM, Al-Ankari AR, Al-Blowi MH, Khan OA, Maken Ali AS, Hedayati A, Garcia Garcia J, Ziay GM, Shoushtari A, Al Qahtani KN, Capua I, Holmes EC, Cattoli G. 2011. Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. J Virol 85: 8413-8421. http://dx.doi.org/10.1128/JVI.00219-11.
14. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris JS, Guan Y. 2005. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 43: 5760-5767. http://dx.doi.org/10.1128/JCM.43.11.5760-5767.2005.
15. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R, Cox N, Hay A. 2000. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A 97: 9654-9658. http://dx.doi.org/10.1073/pnas.160270697.
16. Sun Y, Qin K, Wang J, Pu J, Tang Q, Hu Y, Bi Y, Zhao X, Yang H, Shu Y, Liu J. 2011. High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1/2009 influenza viruses. Proc Natl Acad Sci U S A 108: 4164-4169. http://dx.doi.org/10.1073/pnas.1019109108.
17. Matrosovich MN, Krauss S, Webster RG. 2001. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology 281: 156-162. http://dx.doi.org/10.1006/viro.2000.0799.
18. Wan H, Perez DR. 2007. Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells. J Virol 81: 5181-5191. http://dx.doi.org/10.1128/JVI.02827-06.
19. Sorrell EM, Wan H, Araya Y, Song H, Perez DR. 2009. Minimal molecular constraints for respiratory droplet transmission of an avianhuman H9N2 influenza A virus. Proc Natl Acad Sci U S A 106: 7565-7570. http://dx.doi.org/10.1073/pnas.0900877106.
20. Guan Y, Shortridge KF, Krauss S, Chin PS, Dyrting KC, Ellis TM, Webster RG, Peiris M. 2000. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China. J Virol 74: 9372-9380. http://dx.doi.org/10.1128/JVI.74.20.9372-9380.2000.
21. Iqbal M, Yaqub T, Reddy K, McCauley JW. 2009. Novel genotypes of H9N2 influenza A viruses isolated from poultry in Pakistan containing NS genes similar to highly pathogenic H7N3 and H5N1 viruses. PLoS One 4: e5788. http://dx.doi.org/10.1371/journal.pone.0005788.
22. Zhang P, Tang Y, Liu X, Liu W, Zhang X, Liu H, Peng D, Gao S, Wu Y, Zhang L, Lu S, Liu X. 2009. A novel genotype H9N2 influenza virus possessing human H5N1 internal genomes has been circulating in poultry in eastern China since 1998. J Virol 83: 8428-8438. http://dx.doi.org/10.1128/JVI.00659-09.
23. Wan H, Sorrell EM, Song H, Hossain MJ, Ramirez-Nieto G, Monne I, Stevens J, Cattoli G, Capua I, Chen LM, Donis RO, Busch J, Paulson JC, Brockwell C, Webby R, Blanco J, Al-Natour MQ, Perez DR. 2008. Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential. PLoS One 3: e2923. http://dx.doi.org/10.1371/journal.pone.0002923.
24. Kimble JB, Sorrell E, Shao H, Martin PL, Perez DR. 2011. Compatibility of H9N2 avian influenza surface genes and 2009 pandemic H1N1 internal genes for transmission in the ferret model. Proc Natl Acad Sci U S A 108: 12084-12088. http://dx.doi.org/10.1073/pnas.1108058108.
25. García-Sastre A, Schmolke M. 2014. Avian influenza A H10N8-a virus on the verge? Lancet 383: 676-677. http://dx.doi.org/10.1016/S0140-6736(14)60163-X.
26. Liu D, Shi W, Gao GF. 2014. Poultry carrying H9N2 act as incubators for novel human avian influenza viruses. Lancet 383: 869. http://dx.doi.org/10.1016/S0140-6736(14)60386-X.
27. Wodal W, Falkner FG, Kerschbaum A, Gaiswinkler C, Fritz R, Kiermayr S, Portsmouth D, Savidis-Dacho H, Coulibaly S, Piskernik C, Hohenadl C, Howard MK, Kistner O, Barrett PN, Kreil TR. 2012. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate. Vaccine 30: 4625-4631. http://dx.doi.org/10.1016/j.vaccine.2012.04.102.
28. Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, Mischler R, Zambon MC, Stephenson I. 2009. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 28: 171-178. http://dx.doi.org/10.1016/j.vaccine.2009.09.103.
29. Stephenson I, Nicholson KG, Glück R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. 2003. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362: 1959-1966. http://dx.doi.org/10.1016/S0140-6736(03)15014-3.
30. Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG, Barrett PN. 2007. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036. http://dx.doi.org/10.1016/j.vaccine.2007.05.013.
31. Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Brühl P, Kreil TR, Ehrlich HJ, Barrett PN. 2010. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 5: e9349. http://dx.doi.org/10.1371/journal.pone.0009349.
32. Wichmann BA, Hill ID. 1982. Algorithm 183. An efficient and portable pseudo-random number generator. Appl Stat 31: 188-190.
33. McLeod A. 1985. Remark AS R58. A remark on algorithm AS 183. An efficient and portable pseudo-random number generator. Appl Stat 121: 811-822.
34. U.S. FDA. 2011. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
35. U.S. FDA. 2001. Guidance for industry: bioanalytical method validation U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Veterinary Medicine, U.S. FDA, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
36. ICH. 2005. ICH harmonised tripartite guideline: validation of analytical procedures: text and methodology. Q2(R1). International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q2-R1/Step4/Q2-R1-Guideline.pdf.
37. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937-943.
38. Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN. 2012. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine 30: 4543-4551. http://dx.doi.org/10.1016/j.vaccine.2012.03.061.
39. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. 2009. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361: 2405-2413. http://dx.doi.org/10.1056/NEJMoa0907413.
40. Loew-Baselli A, Pavlova BG, Fritsch S, Poellabauer EM, Draxler W, Kistner O, Behre U, Angermayr R, Neugebauer J, Kirsten K, Förster-Waldl E, Koellges R, Ehrlich HJ, Barrett PN. 2012. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory. Vaccine 30: 5956-5966. http://dx.doi.org/10.1016/j.vaccine.2012.07.039.
41. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, Hartel G, Lai M, Basser R, Gittleson C, Greenberg M. 2010. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303: 37-46. http://dx.doi.org/10.1001/jama.2009.1911.
42. Schild GC, Pereira MS, Chakraverty P. 1975. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 52: 43-50.
43. Agresti A, Coull BA. 1996. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 52: 1103-1111. http://dx.doi.org/10.2307/2533072.
44. Atmar RL, Keitel WA, Quarles JM, Cate TR, Patel SM, Nino D, Wells J, Arden N, Guo K, Hill H, Couch RB. 2011. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine 29: 8066-8072. http://dx.doi.org/10.1016/j.vaccine.2011.08.044.
45. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. 2006. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43: 1135-1142. http://dx.doi.org/10.1086/508174.
46. Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R. 2010. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126: e762-e770. http://dx.doi.org/10.1542/peds.2009-2628.
47. Vesikari T, Forstén A, Herbinger KH, Della Cioppa G, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. 2012. Safety and immunogenicity of an MF59-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 30: 1388-1396. http://dx.doi.org/10.1016/j.vaccine.2011.12.009.
48. Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R. 2012. Homologous and heterologous antibody responses to a one-year booster dose of an MF59 adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 8: 921-928. http://dx.doi.org/10.4161/hv.20248.
49. EMA. 2012. Pandemic influenza vaccine H5N1 Baxter AG: pandemic influenza vaccine (H1N1) (whole virion, inactivated, prepared in cell culture). European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/ema/index.jsp?curl-pages/medicines/human/medicines/001200/human-med-001215.jsp&murl-menus/medicines/medicines.jsp&mid-WC0b01ac058001d124.
50. EMA. 2012. EPAR summary for the public: Vepacel influenza vaccine (whole virion, inactivated). European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/002089/WC500124226.pdf.
51. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Niño D, Belmont JW. 2013. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207: 974-981. http://dx.doi.org/10.1093/infdis/jis935.
52. Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, Kachurina O, Klippel J, Bodle J, Pearse M, Middleton D. 2013. Neuraminidase-inhibiting antibody is a correlate of cross-protetion against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 87: 3053-3061. http://dx.doi.org/10.1128/JVI.02434-12.
53. Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR. 2012. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 205: 28-34. http://dx.doi.org/10.1093/infdis/jir711.
54. Barrett PN, Portsmouth D, Ehrlich HJ. 2010. Developing cell culturederived pandemic vaccines. Curr Opin Mol Ther 12: 21-30.
55. Barrett PN, Portsmouth D, Ehrlich HJ. 2013. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert Rev Vaccines 12: 395-413. http://dx.doi.org/10.1586/erv.13.21.